All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is an independent medical education platform. This activity is supported by an educational grant from Lilly. Funders are allowed no direct influence on our content.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View psoriasis and psoriatic arthritis content recommended for you
ACR 2026 | Top abstracts: What’s hot in psoriatic disease?
To help navigate the exciting content being presented at the American College of Rheumatology (ACR) Convergence 2026, November 6–11, 2026, Orlando, US, the PsOPsA Hub Steering Committee have provided their recommendations for the top abstracts to look out for in psoriatic disease.
| Oral presentations: Sunday, November 8 | |||
| Abstract | Title | Presenter | Time (EST) |
| 0867 | Weight loss following GLP-1 receptor agonist initiation is associated with improved patient reported outcomes in rheumatoid arthritis and psoriatic arthritis | Jeffrey Curtis | 10:15–10:30 |
| 0879 | Identification of protein signatures tracking changes of disease activity of PsA disease domains and improvement with deucravacitinib treatment in phase 3 clinical studies | Vinod Chandran | 08:45–09:00 |
| 0881 | Difficult-to-treat psoriasis identifies patients at increased risk of incident psoriatic arthritis: A population-based time-varying cohort study | Paula David | 09:15–09:30 |
| Oral presentations: Tuesday, November 10 | |||
| Abstract | Title | Presenter | Time (EST) |
| 2804 | Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 24-Week results from a head-to-head, multicenter, randomized, phase 3b study | Joseph Merola | 10:15–10:30 |
| Oral presentations: Wednesday, November 11 | |||
| Abstract | Title | Presenter | Time (EST) |
| 2942 | Ixekizumab plus tirzepatide demonstrated greater disease control at 52 weeks versus ixekizumab alone with incremental improvement from Week 36 in adults with psoriatic arthritis and overweight or obesity: Results from a randomised clinical trial | Joseph Merola | 09:45–10:00 |
| 2943 | Biomarker-driven insights from the phase 2a AFFINITY study evaluating guselkumab + golimumab combination therapy versus guselkumab monotherapy in psoriatic arthritis | Iain McInnes | 10:00–10:15 |
| Posters | |||
| Abstract | Title | Presenter | Date and time (EST) |
| 0344 | A phase 4, prospective, open-label study to assess the effectiveness of adding tirzepatide after initiation of ixekizumab in adults with psoriatic arthritis and overweight or obesity | Catherine Bakewell | Sunday, November 8, 10:30–12:30 |
| 0348 | Baseline characteristics and 12-month effectiveness of guselkumab and IL-17 inhibitors among participants with oligoarticular psoriatic arthritis in the global PsABIOnd study | Frank Behrens | Sunday, November 8, 10:30–12:30 |
| 0358 | Effectiveness of guselkumab vs golimumab in participants with active psoriatic arthritis and inadequate response to one prior tumor necrosis factor inhibitor: Interim results at 6 months in a phase 3b, randomized, open-label, pragmatic trial | Alexis Ogdie | Sunday, November 8, 10:30–12:30 |
| 0359 | Efficacy and safety of tildrakizumab in anti-TNF-naïve patients with active psoriatic arthritis: Week 52 results from a phase 3, randomized, double-blind, placebo-controlled trial | Philip Mease | Sunday, November 8, 10:30–12:30 |
| 0368 | Persistence, effectiveness, safety, and patient reported impact of guselkumab and IL-17 inhibitors in psoriatic arthritis: Full population results of the PsABIOnd global observational study over 12 months | Laure Gossec | Sunday, November 8, 10:30–12:30 |
| 0373 | Treatment with glucagon-like peptide-1 receptor agonists is associated with lower disease activity and pain in psoriatic arthritis independent of weight change | Pankti Mehta | Sunday, November 8, 10:30–12:30 |
| 1306 | Bimekizumab demonstrated maintenance of clinical efficacy responses to 3 years in patients with active psoriatic arthritis from two phase 3 studies | Jessica Walsh | Monday, November 9, 10:30–12:30 |
| 1310 | Cumulative days of musculoskeletal improvement in bio-naïve patients with PsA with or without metabolic syndrome and obesity receiving risankizumab through week 244: Integrated results from the KEEPsAKE clinical trials | Saakshi Khattri | Monday, November 9, 10:30–12:30 |
| 1312 | Efficacy and safety of guselkumab in participants with active psoriatic arthritis and inadequate response/intolerance to one prior tumor necrosis factor inhibitor through 1 year of the SOLSTICE study | Bea Rivard | Monday, November 9, 10:30–12:30 |
| 1313 | Efficacy of izokibep, a novel IL-17A inhibitor, in patients with active psoriatic arthritis: Composite measures of disease activity and patient-reported outcomes from a randomized, double-blind, placebo-controlled, multicenter, phase 2b/3 study | Philip Mease | Monday, November 9, 10:30–12:30 |
| 1314 | Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, phase 3 ONWARD1 and 2 studies | Elisa Muscianisi | Monday, November 9, 10:30–12:30 |
| 1326 | Real-world effectiveness of risankizumab in patients with psoriatic arthritis: 6-month interim results from the observational PErsistence with RISankizumab (PERIS) study | Carlo Selmi | Monday, November 9, 10:30–12:30 |
| 2293 | Efficacy of apremilast in patients with early psoriatic arthritis: A post hoc pooled analysis of seven clinical trials | Philip Mease | Tuesday, November 10, 10:30–12:30 |
| 2295 | Guselkumab efficacy on improvements in American College of Rheumatology response components and association with structural damage progression in participants with active and erosive psoriatic arthritis: Results from a phase 3b, randomized double-blind, placebo-controlled study | Proton Rahman | Tuesday, November 10, 10:30–12:30 |
| 2297 | Ixekizumab and concomitant tirzepatide achieved early disease control in adults with psoriatic arthritis and obesity/overweight: phase 3b TOGETHER-PsA trial | Mohamed Sheesh | Tuesday, November 10, 10:30–12:30 |
| 2313 | Tildrakizumab for the treatment of prior anti-tumor necrosis factor-experienced or -naïve participants with active psoriatic arthritis: Pooled Week 24 results of two Phase 3, randomized, double-blind, placebo-controlled studies, INSPIRE 1 and INSPIRE 2 | Philip Mease | Tuesday, November 10, 10:30–12:30 |
| LB12 | Icotrokinra, an IL-23 receptor targeted oral peptide, in biologic-naïve participants with active psoriatic arthritis: Results through Week 24 of a phase 3, randomized, double-blind, placebo-controlled study | Joseph F. Merola | Tuesday, November 10, 10:30–12:30 |
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
